Study finds protein critical to T cell metabolism, anti-tumour immune response

Must read

How to disable and delete Samsung Pay from your Galaxy phone

When it comes to paying conveniently, Samsung Pay makes using your phone as a bank card an easy process; however, there may come...

How to Hack the Hidden Google Chrome Dinosaur Game

Most of us have seen the dreaded “No Internet” error message on Google Chrome. You can actually turn this screen into a fun,...

Nest Hub Photo Frame loses ‘experimental’ Facebook, Flickr

When not actively in use, many have their Smart Displays cycle through a carousel of pictures. These Assistant devices are closely integrated with...

Xbox Series X restock: how to track Xbox stock on Twitter – and actually get it

Sunday is expected to be slow for our Xbox restock Twitter tracker, which is working overtime to find the Microsoft console in stock,...
Bhawani Singhhttps://techmepro.com
I am a blogger who believes in delivering latest tech news from around the world to my viewers.

WASHINGTON: Researchers at The University of Texas MD Anderson Cancer Center have discovered that a protein called NF-kappa B-inducing kinase (NIK) is essential for the shift in metabolic activity that occurs with T cell activation, making it a critical factor in regulating the anti-tumour immune response.
The preclinical research, published today in Nature Immunology, suggests that elevating NIK activity in T cells may be a promising strategy to enhance the effectiveness of immunotherapy, including adoptive cellular therapies and immune checkpoint blockade.
In a preclinical melanoma model, the researchers evaluated melanoma-specific T cells engineered to express higher levels of NIK. Compared to controls, these T cells displayed stronger tumour-killing abilities and improved survival, suggesting that increasing NIK activity may improve the effectiveness of adoptive T cell therapies.
“NIK is a novel regulator of T cell metabolism that works in a very unique manner. Biologically, NIK activity stabilizes the HK2 glycolytic enzyme through regulating the cellular redox pathway,” said corresponding author Shao-Cong Sun, Ph.D., professor of Immunology.
“From the therapeutic point of view, we were able to improve the efficacy of adoptive T cell therapies in preclinical models by overexpressing NIK in those cells,” added Sun.
T cells generally exist in a relatively quiet state with low energy demands and little cell division, Sun explained. However, upon recognizing an antigen, T cells begin expanding and activate the glycolysis metabolic pathway to meet the increased energy demands of carrying out their immune function.
This metabolic shift is closely regulated by immune checkpoint proteins, such as CTLA-4 and PD-1, which act to repress T cell metabolism. Thus, immune checkpoint inhibitors can reinvigorate T cell anti-tumour activity by boosting metabolism.
In addition, T cells begin producing proteins called costimulatory molecules after they become activated, which work to stimulate metabolism and the immune response.
Knowing that the NIK protein functions downstream of many of these costimulatory molecules, the researchers sought to better understand its role in regulating T cell function.
In melanoma models, NIK loss resulted in an increased tumour burden and fewer tumour-infiltrating T cells, suggesting NIK plays a crucial role in anti-tumour immunity and T cell survival.
Further experiments revealed that NIK is essential for the metabolic reprogramming in activated T cells through its control of the cellular redox system. Increased metabolism can lead to elevated levels of reactive oxygen species (ROS), which can damage the cell and stimulate protein degradation.
The researchers discovered that NIK maintains the NADPH redox system, an important antioxidant mechanism to reduce the accumulation of ROS. This in turn leads to the stabilisation of the HK2 protein, a rate-limiting enzyme within the glycolysis pathway.
“Our findings suggest that without NIK, the HK2 protein is not stable, and is constantly being degraded. You need NIK to maintain HK2 levels in T cells. Interestingly, we found that adding more NIK to the cells, you can further increase the levels of HK2 and make glycolysis more active, Sun said.
As a potential therapeutic application, the researchers currently are working to evaluate modified chimeric antigen receptor (CAR) T cells in the laboratory engineered to overexpress NIK.
In the future, they hope to explore other therapeutic approaches, such as targeted therapies that could manipulate NIK activity in tandem with other immunotherapy approaches, including immune checkpoint inhibitors.

Source link


More articles

Leave a Reply

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

- Advertisement -

Latest article

Study reveals blood tests can offer early indicator of severe Covid-19

WASHINGTON: A recent study has found that a series of biomarkers, or biological signals, associated with white blood cell activation and obesity can...

Amazon Manager Sues Company for Racial Discrimination, Harassment

A manager at Amazon.com sued the online retailer for discrimination on Monday, saying it hires Black people for lower positions and promotes them...

The Google Pixel Recorder App Can Now Back Up Audio to the Cloud for Sharing – Review Geek

GoogleGoogle likes to add new and exclusive features to Pixel phones, and the latest feature drop just arrived. Now, Pixel phones can backup audio...

FAUG developer gets defamation notices after comments on gambling apps

Gambling apps have been actively trying to pass themselves off as gaming ones for a while now and they have started pushing to...

Amazfit GTS 2 Review | NDTV Gadgets 360

The Amazfit GTS 2 is a new wearable from the Xiaomi-backed company Huami, and is now available in India. The smartwatch offers features such as automatic...
- Advertisement -